Back to top
more

BioTechne Corp (TECH)

(Delayed Data from NSDQ)

$54.88 USD

54.88
1,847,280

-0.01 (-0.02%)

Updated Aug 4, 2025 04:00 PM ET

After-Market: $54.87 -0.01 (-0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (143 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Can Stratasys (SSYS) Pull a Surprise This Earnings Season?

by Zacks Equity Research

Launching innovative products, strategic partnerships and acquisitions, along with improving cost efficiencies are likely to are likely to strengthen Stratasys' (SSYS) Q2 results.

    Zacks Equity Research

    Should You Buy Bio-Techne (TECH) Ahead of Earnings?

    by Zacks Equity Research

    Bio-Techne (TECH) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

      Zacks Equity Research

      CyberArk Software (CYBR) Q2 Earnings: Likely to Disappoint?

      by Zacks Equity Research

      CyberArk Software's (CYBR) slowdown in revenue growth, competition from peers and uncertain macroeconomic environment are likely to remain headwinds in Q2.

        Arpita Dutt headshot

        4 Sell-Ranked Drug Stocks Investors Should Avoid Ahead of Earnings

        by Arpita Dutt

        Here is a look at four Sell-Ranked drug stocks with negative earnings ESP that should be avoided ahead of earnings.

          Zacks Equity Research

          Implied Volatility Surging for Bio-Techne (TECH) Stock Options

          by Zacks Equity Research

          Options traders are pricing in a big move for Bio-Techne (TECH) shares as it has huge implied volatility.

            Zacks Equity Research

            Drug Stocks Reporting Earnings on Feb 7: GILD, MNK & More

            by Zacks Equity Research

            Earnings growth turned positive in the last quarter and things are surely looking up as we stand in the middle of the earnings season.